Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation

Area of Science:

• Hematology
• Transplantation Immunology
• Oncology

Background:

• Hematopoietic growth factors accelerate recovery post-autologous bone marrow transplantation (BMT).
• Concerns existed regarding GvHD and relapse risk with growth factors in allogeneic BMT.
• Graft-versus-host disease (GvHD) remains a significant challenge in allogeneic BMT.

Purpose of the Study:

• To evaluate the efficacy and safety of G-CSF in accelerating myeloid engraftment after allogeneic BMT.
• To compare outcomes in patients receiving G-CSF with historical controls.
• To assess G-CSF's impact on GvHD and early mortality in sibling and unrelated donor BMT.

Main Methods:

• Retrospective analysis of 50 patients undergoing allogeneic BMT (30 sibling, 20 unrelated).
• G-CSF administration post-BMT.
• Comparison with historical control groups receiving standard GvHD prophylaxis (cyclosporine/prednisone or methotrexate).
• Assessment of time to absolute neutrophil count > or = 500/microL.

Main Results:

• G-CSF significantly reduced time to myeloid engraftment in sibling BMT recipients (10 vs 13 days, P < .01) and unrelated donor BMT recipients (16 vs 19 days, P < .05).
• No increase in GvHD or early mortality observed in matched sibling BMT.
• Matched unrelated donor BMT with G-CSF showed a low GvHD incidence (21%) but high early mortality (45%).

Conclusions:

• G-CSF is effective in accelerating myeloid engraftment after allogeneic matched sibling BMT.
• G-CSF appears safe regarding GvHD and early mortality in matched sibling BMT.
• Higher early mortality in unrelated donor BMT recipients warrants further investigation and randomized controlled trials.